Remove Bioethics Remove Governance Remove Pharmaceutical Industry Remove Public Health
article thumbnail

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

Bill of Health

Pressure from Senator Bernie Sanders, Chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee seems to have catalyzed the administration to make this move. pharmaceutical market. However, reasonable pricing requirements within federal agreements are not new, nor are the unsubstantiated concerns around them.

COVID-19 205
article thumbnail

Can Rights Make Any Difference for Access to Health? Insights from a Scoping Review on Constitutional Rights for the WHO Council on the Economics of Health for All

Bill of Health

By Luciano Bottini Filho, Camila Gianella Malca, and Alicia Ely Yamin The intersection of health financing and the right to health is a common concern in public health advocacy. However, it is challenging to isolate the mechanisms that connect individuals’ rights with increased public investment.

Bioethics 326
article thumbnail

The Remarkable Rise of Pharma’s Reputation in the Pandemic

Health Populi

The reputation of the pharmaceutical industry gained a “whopping” 30 points between January 2020 and February 2021, based on the latest Harris Poll in their research into industries’ reputations. The study was written up by Beth Snyder Bulik in FiercePharma. The coronavirus re-shaped people in the U.S.

COVID-19 154